Sentiment Trading

Ipsen SA’s Cabometyx has received a positive opinion from the European Medicines Agency for treating advanced neuroendocrine tumors, potentially positioning it as the first approved systemic therapy in the EU.

Ipsen SA’s stock price has stabilized at 102.5 EUR, following significant fluctuations, as the company continues to navigate market challenges and capitalize on growth opportunities in the pharmaceutical industry.